The abstract is read at the publisher; the summary is JClub's.
Week-12 plasma ctDNA after definitive chemoradiotherapy in locally advanced head and neck squamous cell carcinoma detects recurrence with 100% specificity and predicts worse PFS and OS.
- Why it matters: Standard imaging after CRT can miss molecular residual disease, limiting accurate post-treatment risk assessment and timing for ctDNA-based detection.
- What they did: In 74 prospectively enrolled LA-HNSCC patients, plasma-only methylation ctDNA was measured before treatment, at 8 and 12 weeks, and during follow-up, and performance was compared with 12-week PET/CT.
- The result: Detectable week-12 ctDNA yielded 69% sensitivity, 100% specificity, 100% PPV, and 76% NPV for recurrence, and was linked to shorter PFS (HR 6.44) and OS (HR 7.31); longitudinal monitoring found additional recurrences despite initially undetectable week-12 ctDNA.
The findingWhy it mattersWhat they didThe result
AI summary of the abstract · may contain errors · not medical advice · read the paper.